ScripNektar Therapeutics is making Phase III preparations for rezpegaldesleukin, also known as rezpeg, after the potential pipeline-in-a-product hit its main goal in a mid-stage trial for patients with ato
ScripIt looks as though nothing will come of the takeover talks PureTech Health has held with Nordic Capital Epsilon but there is a compelling argument for taking its ‘hub-and-spoke’ business private in th
ScripWho: Grünenthal/Valinor Pharma What: Grünenthal is buying privately held US biotech Valinor on the strength of its lone commercial product, Movantik. Why: Grünenthal is acquiring Valinor to gain
ScripPrivately held Soterios Pharma unveiled positive top-line Phase II data for its alopecia areata candidate STS-01 on 30 May, saying the drug could be positioned to compete with established JAK inhibi